Antabio announces achievement of milestone in the development of its metallo-carbapenemase inhibitor in collaboration with the Wellcome Trust

Feb 27, 2014

Antabio announced today that it has identified a lead series of pan-metallo beta-lactamase inhibitors that, in combination with carbapenems, restores antibacterial activity against life-threatening clinical isolates whilst exhibiting no toxicity or developmental...

Antabio awarded EUR 742,000 (USD 1,02 million) funding from Bpifrance to support the discovery of New Gram-Negative Anti-Infective Agents

Nov 13, 2013

Antabio and Bpifrance, the French public investment bank, announce that Antabio will receive EUR 742,000 (USD 1,02 million) in funding from Bpifrance to support the discovery, evaluation and development of new adjunctive antibiotic therapies. Within the...

Antabio’s antibacterial programme receives € 4.7 Million Award from the Wellcome Trust

Feb 1, 2013

Antabio, a French biopharmaceutical company, has received a €4.7 Million Wellcome Trust Seeding Drug Discovery Award to develop novel small molecule drugs for the treatment of life-threatening infections caused by multi-drug resistant Gram-negative bacteria.Multi-drug...

Argenta and Antabio Announce Drug Discovery Collaboration

Jan 31, 2013

Harlow, UK and Labège, France – Argenta, a Galapagos NV (Euronext: GLPG) company that provides drug discovery services from target validation to proof of concept, announced today that it has signed a collaboration agreement with Antabio. Under the terms of the...

Antabio and WiSEED announce the first successful round of crowdfunding applied to biotech start-up financing

Oct 1, 2012

Antabio, the biopharmaceutical antibacterial drug discovery company, and WiSEED, the French crowdfunding platform dedicated to innovative & technologic startups, announce the successful completion of their seed round of financing with a profitable exit of the...